Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
Algorae signs two-part deal with Umedica to expand Australian portfolio
October 19, 2026 - - Latest News -
Novartis, Boehringer Ingelheim leaders join Medicines Australia board
October 19, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5. Ep.36
October 19, 2026 - - Podcast -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Global headwinds and new contenders set the agenda for Australia's 'Biggest Week in Biotech'
October 19, 2026 - - Latest News -
Mixed PBAC outcomes for multi-cancer immunotherapy listings
October 19, 2026 -